Results 21 to 30 of about 1,190,584 (342)

Salivary cytokine panel indicative of non-small cell lung cancer. [PDF]

, 2018
Objective To develop a combinatorial panel of salivary cytokines that manifests the presence of non-small cell lung cancer (NSCLC) that will eventually improve prognosis by facilitating the early diagnosis and management of this common cancer. Methods We
Koizumi, Tomonobu, Shetty, Vivek, Yamaguchi, Masaki   +2 more
core   +3 more sources

Deep segmentation networks predict survival of non-small cell lung cancer [PDF]

, 2019
Non-small-cell lung cancer (NSCLC) represents approximately 80-85% of lung cancer diagnoses and is the leading cause of cancer-related death worldwide. Recent studies indicate that image-based radiomics features from positron emission tomography-computed
Allen, Bryan, Baek, Stephen, Baek, Stephen, Buatti, John, Cabel, Katherine, Diehn, Maximilian, Gannon, Maggie, He, Yusen, Kim, Yusung, Loo, Billy, Plichta, Kristin, Seyedin, Steven, Smith, Brian, Sun, Zhiyu, Tong, Ling, Wu, Jia, Wu, Xiaodong   +16 more
core   +2 more sources

Non-small cell lung cancer [PDF]

, 2018
Lung cancer has the highest cancer-related mortality rate worldwide, mainly because of late diagnosis and the emergence of treatment resistance as a result of tumor heterogeneity. Tumor cells within the same tumor respond differently to treatment.
Michael Wahl, Matthew A. Gubens, Sue S. Yom   +2 more
  +5 more sources

Characteristics and outcome of patients with newly diagnosed advanced or metastatic lung cancer admitted to intensive care units (ICUs) [PDF]

, 2018
BACKGROUND: Although patients with advanced or metastatic lung cancer have poor prognosis, admission to the ICU for management of life-threatening complications has increased over the years.
A Steven, A-C Barbot, A-C Toffart, AK Adam, C Hamard, CA Reichner, CG Slatore, DV Schapira, E Azoulay, E Azoulay, E Biskup, F Vincent, FS Taccone, JI Salluh, JL Vincent, JR Gall Le, K Puxty, M Früh, M Garrouste-Orgeas, M Maltoni, M Soares, M Soares, M Soares, ME Charlson, MM Oken, MR Bonomi, P Zarogoulidis, R Fisher, RR Jennens, S Anisoglou, S Roques, T Cooksley, T Tanvetyanon, X Nan, Y Zerbib, Y-F Chen, YJ Kim   +36 more
core   +2 more sources

Staging non-small cell lung cancer [PDF]

Cancer Imaging, 2007
Patients with newly diagnosed non-small cell lung cancer (NSCLC) need accurate tumor staging in order to direct appropriate therapy and establish prognosis; the tumor is usually staged using the TNM system. The major imaging modalities currently used for staging this disease are thoracic computed tomography (CT) (including the adrenal glands) and whole
openaire   +2 more sources

Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells [PDF]

, 2016
Cancer stem cells (CSCs) play an important role in tumor initiation, progression, therapeutic failure and tumor relapse. In this study, we evaluated the efficacy of the thiazole derivative 3-methylcyclopentylidene-[4-(4’-chlorophenyl)thiazol-2-yl ...
Buglioni, Simonetta, Carradori, Simone, DE LUCA, Teresa, De Maria, Ruggero, Del Bufalo, Donatella, Desideri, Marianna, DI MARTILE, Marta, Eramo, Adriana, Gabellini, Chiara, Mai, Antonello, Milella, MICHELE STANISLAW, Rotili, Dante, Secci, Daniela, Sette, Giovanni, Trisciuoglio, Daniela   +14 more
core   +8 more sources

Dry Small Pleural Dissemination of Adenocarcinoma of the Lung Preoperatively Detected by PET/CT: A Report of Two Cases [PDF]

, 2008
Dry pleural dissemination in non-small cell lung cancer, defined as solid pleural metastasis of lung cancer without pleural eff usion, is a condition occurring in T4 lung cancer.
Aoe, Motoi, Date, Hiroshi, Okutani, Daisuke, Oto, Takahiro, Sano, Yoshifumi, Toyooka, Shinichi, Yamane, Masaomi   +6 more
core   +1 more source

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [PDF]

, 2004
BACKGROUND: Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).
Bell, D. W., Brannigan, B. W., Christiani, D. C., Gurubhagavatula, S., Haber, D. A., Haluska, F. G., Harris, P. L., Haserlat, S. M., Louis, D. N., Lynch, T. J., Okimoto, R. A., Settleman, J., Sordella, R., Supko, J. G.   +13 more
core   +1 more source

Chinese Expert Consensus on the Standardized Diagnosis and Treatment of 
Non‑small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)

Chinese Journal of Lung Cancer
The standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon ...
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
doaj   +1 more source